Phenotypes Associated with This Genotype

Genotype
MGI:3762559

• Allelic Composition: Gt(ROSA)26Sor^tm1Sor/Gt(ROSA)26Sor⁺; Tg(Nphs1-cre)33Mska/0; Tg(Nphs1-IL2RA)18Mska/0
• Genetic Background: involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * DBA/2

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

renal/urinary system

increased kidney cell proliferation ( J:126591 )

• proliferation of parietal epithelial cells, not podocytes, is observed; proliferating cells are lacZ-negative, whereas podocytes express beta-galactosidase

abnormal glomerular capsule parietal layer morphology ( J:126591 )

• vacuolar degeneration of parietal epithelial cells is observed after LMB2 treatment

• proliferation of parietal epithelial cells, not podocytes, is also seen; proliferating cells are lacZ-negative, whereas podocytes express beta-galactosidase

abnormal podocyte morphology ( J:126591 )

• vacuolar degeneration of podocytes is observed after LMB2 treatment; podocytes are identified by lacZ staining

• podocytes are lost temporally after LMB2 treatment, correlating with progression of sclerosis

abnormal renal glomerulus morphology ( J:126591 )

• hyalinosis is seen after LMB2 treatment

mesangiolysis ( J:126591 )

• mesangiolysis is seen after LMB2 treatment

glomerulosclerosis ( J:126591 )

• after treatment with the immunotoxin LMB2, transgenic animal rapidly develop glomerulosclerosis

• 18%, 23%, and 60% of glomeruli show segmental or global sclerosis at 10, 14 or 21 days after treatment, respectively

cellular

increased kidney cell proliferation ( J:126591 )

• proliferation of parietal epithelial cells, not podocytes, is observed; proliferating cells are lacZ-negative, whereas podocytes express beta-galactosidase